Analytical Services Fact Sheet
Supporting Preformulation, Formulation Development, Quality Control and Stability Testing of APIs and Final Dosage Form
Upperton provides an extensive range of analytical techniques to generate critical product data from the early stages of development through to QC testing of clinical supplies. This data guides formulation development and is used to assess stability and evaluate the performance
and quality of the final dosage form.
Preformulation/Formulation Development
Our scientists recognise that successful development programmes begin with a thorough understanding of the physico-chemical characteristics of the API, and any potential stability or excipient incompatibility challenges.
Traditional Methods
HLPC
Dissolution
Spectrophotometric Analysis
FTIR
Karl Fischer
Physical Characterisation
Laser Particle Sizing
Electron Microscopy
Differential Scanning Calorimetry
X-Ray Diffraction
Dynamic Vapour Sorption
Powder Rheology
Dosage Form Testing
NGI Powder Deposition (Pulmonary)
AINI Deposition (Nasal)
Nasal Spray Characterisation
Dissolution Testing (Biorelevant & Traditional)
Biologics
Gel Electrophoresis
Western Blotting
ELISA
Spectrophotometric Analysis
Sub-Visible Particulates
Assays are developed and qualified to a phase-appropriate level to provide confidence in the
data generated.
Stability Testing
Stability assessment is critical to a successful development programme, regardless of stage.
During the early stages of formulation development, Upperton uses Accelerated Stability Assessment Program (ASAPprime®) to generate phase-appropriate stability data. The use of ASAPprime® helps us to rapidly pinpoint potential instability issues associated with our customers’ API and identify formulation strategies to overcome these stability challenges.
During the final stages of clinical formulation, more formal ICH stability studies on the Technical and Clinical batches will be performed to generate stability data to support regulatory
submissions.
GMP Manufacture: In Process and Finished Product Release Training
Any analytical methods used need to be robust, yet phase-appropriate and of sufficient quality to support the appropriate regulatory submissions.
QC in process and release testing of clinical products confirm the dose strength/assay in the drug product and the level of any impurities derived from the API. Performance testing may include tablet/capsule dissolution or impaction testing (NGI) to assess the aerodynamic delivery of powder nasal and pulmonary devices. Microbial limits testing is used to ensure that the drug product complies with the relevant specification for microbial quality for the dosage form.
